[3H]Glibenclamide-Binding Protein, a Putative Neuronal

Total Page:16

File Type:pdf, Size:1020Kb

[3H]Glibenclamide-Binding Protein, a Putative Neuronal Proc. Natl. Acad. Sci. USA Vol. 85, pp. 9816-9820, December 1988 Neurobiology Characterization, purification, and affinity labeling of the brain [3H]glibenclamide-binding protein, a putative neuronal ATP-regulated K+ channel (sulfonylurea/ischemia) HENRI BERNARDI, MICHEL FOSSET, AND MICHEL LAZDUNSKI* Centre de Biochimie, Centre National de la Recherche Scientifique, Parc Valrose, 06034 Nice Cedex, France Communicated by Jean-Marie Lehn, September 7, 1988 (received for review May 6, 1988) ABSTRACT Sulfonylurea and particularly glibenclamide ATP, and wheat germ agglutinin (WGA) were purchased are potent blockers of ATP-regulated K+ channels in insulin- from Sigma. ADP-agarose type 4 (ADP attached through the secreting cells. A very good correlation exists between binding ribose hydroxyls by means of periodate oxidation), AMP- of sulfonylurea to brain and insulinoma cell membranes. The agarose, and GMP-agarose gels were from Pharmacia. Hy- [3H]glibenclamide-binding component from pig brain micro- droxylapatite (HA-Ultrogel) was from IBF (Villeneuve- somes was solubilized with digitonin with a complete retention la-Garenne, France). Pig brains were collected at the local of its properties of interaction with glibenclamide and other slaughterhouse 30 min after death and immediately stored in sulfonylureas. A four-step purification was achieved that used liquid nitrogen until processed. (i) hydroxylapatite chromatography, (ii and iii) affinity chro- Microsome Preparation and Solubilization of [3H]Gliben- matographies on ADP-agarose and wheat germ agglutinin- clamide-Binding Sites. Microsomes were prepared from pig agarose columns, and (iv) a rmal chromatographic step on a brain cortex in 40 mM imidazole hydrochloride buffer (pH mixture of AMP-agarose/GMP-agarose/hydroxylapatite. This 6.5) in the presence of a mixture of protease inhibitors [1 mM procedure led to a 2500-fold purification. NaDodSO4/poly- EDTA/1 mM iodoacetamide (IAA)/0.1 mM phenylmethyl- acrylamide gel electrophoresis of the purified material in reduc- sulfonyl fluoride (PMSF)/10 gg of soybean trypsin inhibitor ing and nonreducing conditions showed that the sulfonylurea- (STI) per ml/10 ,M leupeptin]. Fifteen grams of pig cortex binding component is made of a single major polypeptide chain was homogenized in 500 ml of buffer at 40C with a Polytron of Mr 150,000 ± 10,000. Direct photoafmnity labeling of the PT10 homogenizer (Kinematica GmbH, Lucerne, Switzer- receptor with [3H]glibenclamide at different steps of the purifi- land) (setting 6, 1 min) and centrifuged as described (11) to cation also showed that radioactivity was specifically incorpo- obtain microsomes. rated into a polypeptide ofMr 150,000 ± 5000, thus confirming Pig brain microsomes were pelleted at 80,000 x g for 20 min the subunit structure indicated by the purification. and resuspended in the solubilization buffer (1.8% digitonin/ 100 mM KCI/ 40 mM imidazole hydrochloride, pH 6.5/1 mM ATP-sensitive K+ channels have recently been identified in IAA/0.1 mM PMSF/10 ,ug of STI per ml/10 ,uM leupeptin) pancreatic beta cells, cardiac cells, and skeletal muscle cells to give a final concentration of 5-8 mg of protein per ml. The (1-3). Their physiological role is best understood in pancre- solution was agitated for 1 hr at 4°C and centrifuged at 135,000 atic beta cells, in which their blockade in response to glucose x g for 20 min. The supernatant was then collected and stored perfusion involves a depolarization that triggers repetitive at 4°C for a maximum of 24 hr. electrical activity that subsequently provokes Ca2" entry and (3HjGlibenclamide-Binding Assay. For equilibrium binding insulin secretion (3). studies, intact and solubilized microsomes (500 ,g/ml) were Sulfonylureas are hypoglycemic agents that have been incubated in the presence of increasing concentrations of used for a long time in the treatment of diabetes mellitus (4). [3H]glibenclamide for 1 hr at 4°C. The assay medium was It is now well established that molecules in this family of buffered with 20 mM imidazole hydrochloride (pH 6.5). drugs are specific blockers of ATP-regulated K+ channels in When working with intact microsomes, bound and free insulin-secreting cells (5-7) and cardiac cells (8). ligands were separated by filtration of aliquots on GF/C Binding sites for [3H]glibenclamide, the most potent sul- Whatman filters. Filters were rapidly washed twice with 6 ml fonylurea (6-8), have now been identified in pancreatic beta of ice-cold 100 mM Tris HCI (pH 7.5) and radioactivity was cells (7, 9, 10), cardiac cells (8), and brain membranes (9). counted in Biofluor liquid scintillation fluid (New England This paper reports the identification by purification and by Nuclear). For binding studies with solubilized microsomes, photoaffinity labeling of the subunit structure of the [3H]- samples of 200 ,l were loaded onto 5 ml of Sephadex G-50 glibenclamide-binding protein from pig brain cortex, which is medium columns equilibrated with 0.05% 3-[(3-cholamido- presumably associated with a neuronal ATP-regulated K+ propyl)dimethylammonio]-1-propanesulfonate/20 mM imi- channel. dazole hydrochloride, pH 6.5. The bound radioactivity was eluted by 2.4 ml of0.5 M NaCl and fractions were assayed for MATERIALS AND METHODS radioactivity as described above. Specific [3H]glibenclamide = binding was calculated by subtraction from the total binding Materials. [3H]Glibenclamide (50 Ci/mmol; 1 Ci 37 GBq) ofthe nonspecific binding component determined in a parallel was from Hoechst. Clorpropamide, HB699, tolbutamide, unlabeled 1 carbutamide, gliclazide, glibornuride, glipizide, glisoxepide, incubation with ,M glibenclamide. gliquidone, and glibenclamide were generously provided by Roche, Schering, Servier, and Pfizer. Digitonin, Abbreviations: ADP-agarose type 4 column, ADP attached through Hoechst, the ribose hydroxyls by means of periodate oxidation; HA-Ultrogel, hydroxylapatite; IAA, iodoacetamide; PMSF, phenylmethylsulfonyl The publication costs of this article were defrayed in part by page charge fluoride; STI, soybean trypsin inhibitor; WGA, wheat germ agglu- payment. This article must therefore be hereby marked "advertisement" tinin. in accordance with 18 U.S.C. §1734 solely to indicate this fact. *To whom reprint requests should be sent. 9816 Downloaded by guest on September 28, 2021 Neurobiology: Bernardi et al. Proc. Natl. Acad. Sci. USA 85 (1988) 9817 In competition experiments between [3H]glibenclamide solubilization, only digitonin, Nonidet P-40, and 3-[3-cholami- and unlabeled sulfonylureas, intact or solubilized micro- dopropyl)dimethylammonio]-1-propanesulfonate were able to somes were incubated for 1 hr at 4TC in the presence of 1 nM solubilize the [3H]glibenclamide-binding component with a [3H]glibenclamide and of various concentrations of the un- high yield. Other detergents, such as cholate, desoxycholate, labeled compounds. Lubrol PX, Tween 20, Triton X-100, Emulphogen BC720, Association and Dissociation Kinetics. Kinetics of associa- and Empigen BB/P, only solubilized the [3H]glibenclamide tion of [3H]glibenclamide to its solubilized receptor were receptor but with a very low efficiency. Solubilization with measured with 1 nM [3H]glibenclamide added at time zero. Nonidet P-40 produced a labile receptor (ti/2 = 2 hr) that could Aliquots were taken at different times and the bound radio- not be stabilized by adding phospholipids or glycerol. Digi- activity was measured by the techniques described above. tonin was the only detergent that allowed adequate solubili- When the level of specifically bound [3H]glibenclamide had zation permitting purification of the [3H]glibenclamide-bind- reached a plateau value, dissociation was started by adding ing component. The most successful solubilization of the a large excess (5 /iM) of glibenclamide. [3H]glibenclamide receptor was obtained with 1.8% digito- Chromatographies on HA-Ultrogel, ADP-Agarose, WGA- nin, giving a yield of 40% ± 5% of active receptor. High Affi-Gel, AMP-Agarose, and GMP-Agarose Columns. HA- concentrations of KCI (up to 1 M), NaCl (up to 2 M), or Ultrogel columns (40 ml) were equilibrated in 0.05% digitonin (up to 2%) did not interfere with [3H]glibenclamide digitonin/100 mM KCI/40 mM imidazole hydrochloride, pH binding. In contrast to observations made in the course of 6.5/1 mM IAA/0.1 mM PMSF. Solubilized microsomes (70 purification ofthe Na' channel (15, 16) or the skeletal muscle ml, 175 mg of protein) were loaded on the column and eluted Ca2+ channel (17), the addition of phospholipids and/or with the same buffer. The eluate was adjusted to a final glycerol failed to increase the of the concentration of 150 mM KCl/1 mM EDTA and applied to stability sulfonylurea the ADP-agarose column (15 ml) equilibrated in buffer A receptor. (0.1% digitonin/150 mM KCI/40 mM imidazole hydrochlo- [3H]Glibenclamide equilibrium binding studies indicate ride, pH 6.5/1 mM IAA/0.1 mM PMSF). The column was that this sulfonylurea specifically binds to a single class of first washed with 30 ml of the equilibration buffer and then noninteracting sites in intact and solubilized microsomes washed with 30 ml of a buffer containing 0.1% digitonin, 300 (Fig. 1 A and B). The apparent equilibrium dissociation mM NaCl, 1 mM IAA, 0.1 mM PMSF, and 40 mM imidazole constants (Kd) and the maximal binding capacities (Bmax) hydrochloride (pH 6.5). Elution was carried out with buffer relative to [3H]glibenclamide interaction were identical for A containing 3 mM ATP. Five-milliliter fractions were intact and solubilized microsomes: Kd = 0.8 + 0.3 nM and collected and assayed for [3H]glibenclamide binding and Bmax = 400 ± 50 fmol/mg (Fig. 1 A Inset and B Inset c). protein concentration. Active fractions were pooled and Association and Dissociation Kinetics. Typical kinetics of recycled for 2 hr on a WGA-Affi-Gel column (10 ml) that was association of [3H]glibenclamide to detergent extracts of equilibrated overnight in buffer A. After washing with 40 ml brain microsomes are presented in Fig. 1B Insets a and b.
Recommended publications
  • Effect of Glucose/Sulfonylurea Interaction on Release of Insulin
    Proc. Nati. Acad. Sci. USA Vol. 76, No. 11, pp. 5901-5904, November 1979 Medical Sciences Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas (glibenclamide) SUAD EFENDIt*, FRANZ ENZMANNf, ANITA NYLtN*, KERSTIN UVNAS-WALLENSTENt, AND ROLF LUFT* *Department of Endocrinology, Karolinska Hospital, 104 01 Stockholm; tDepartment of Pharmacology, Karolinska Institute, 104 01 Stockholm, Sweden; and tHoechst Aktiengesellschaft, Medizinische Abteilung, Frankfurt, West Germany Contributed by Rolf Luft, July 27, 1979 ABSTRACT The effect of a sulfonylurea, glibenclamide, method and separated on CM-cellulose column. The antibodies on the release of insulin, glucagon, and somatostatin was studied produced in our laboratory were used at a final dilution of 1: in the isolated perfused rat pancreas. At concentrations glucose 56,000. Crossreactivity of the antibody was less than 0.01% with of 1.1 mM or less, the drug stimulated somatostatin release, whereas glucagon release, after 2-3 min of increase, was insulin, glucagon, substance P, luliberin, vasopressin, and ox- markedly inhibited. Insulin release was moderately stimulated, ytocin. The antigenic specificity of the antibodies was deter- and maximal release occurred relatively late. A moderate glu- mined by using somatostatin analogues (11). Phosphate buffer cose load (6.7 mM) inhibited glibenclamide-induced release of (0.04 M, pH 7.4) containing 1% bovine serum albumin was used somatostatin, whereas the two in combination exerted an ad- as the diluent for all components in this radioimmunoassay. ditive action on insulin release. Greater glucose loads, which by themselves would stimulate somatostatin release, only Incubations were for 48 hr at 4°C.
    [Show full text]
  • (Trulicity) Pen and the Semaglutide (Ozempic) Pen
    Protocol H9X-MC-B021(b) Crossover Study Comparing Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen NCT03724981 Approval Date: 30-Nov-2018 H9X-MC-B021(b) Clinical Protocol Page 1 Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of dulaglutide (LY2189265), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Dulaglutide (LY2189265) Eli Lilly and Company Indianapolis, Indiana USA 46285 Protocol Electronically Signed and Approved by Lilly on 07 Aug 2018 Amendment (a) Electronically Signed and Approved by Lilly on 11 Sep 2018 Amendment (b) Electronically Signed and Approved by Lilly on date below Approval Date: 30-Nov-2018 GMT LY2189265 H9X-MC-B021(b) Clinical Protocol Page 2 Table of Contents Section Page Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen ............................................................1 Table of Contents........................................................................................................................2 1.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Enhancement of Dissolution and Oral Bioavailability of Gliquidone with Hydroxy Propyl-Β-Cyclodextrin
    ORIGINAL ARTICLES Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad, India Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-b-cyclodextrin S. Sridevi, A. S. Chauhan, K. B. Chalasani, A. K. Jain, P. V. Diwan Received November 15, 2002, accepted May 5, 2003 Dr. Prakash V. Diwan, Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad – 500 007 A.P., India [email protected] Pharmazie 58: 807–810 (2003) The virtual insolubility of gliquidone in water results in poor wettability and dissolution characteristics, which may lead to a variation in bioavailability. To improve these characteristics of gliquidone, binary systems with hydroxypropyl-b-cyclodextrin (HP-b-CD) were prepared by classical methods such as physical mixing, kneading, co-evaporation and co-lyophilization. The solid state interaction between the drug and HP-b-CD was assessed by evaluating the binary systems with X-ray diffraction, differen- tial scanning calorimetry and IR- spectroscopy. The results establish the molecular encapsulation and amorphization of gliquidone. The phase solubility profile of gliquidone in aqueous HP-b-CD vehicle À1 resulted in an AL type curve with a stability constant of 1625 M . The dissolution rate of binary sys- tems was greater than that of pure drug and was significantly higher in the case of co-lyophilized and co-evaporated systems. Upon oral administration, [AUC]0-a was significantly higher in case of co-lyo- philized (2 times) and co-evaporated systems (1.5 times) compared to pure drug suspension while other binary systems showed only a marginal improvement. The study ascertained the utility of HP-b- CD in enhancing the oral bioavailability of gliquidone, and points towards a strong influence of the preparation method on the physicochemical properties.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Journal of Diabetes and Obesity
    Journal of Diabetes and Obesity Research Article Open Access The Different Association between Metformin and Sulfony- lurea Derivatives and the Risk of Cancer May be Confounded by Body Mass Index Catherine E. de Keyser1,2, Loes E. Visser1, Albert Hofman1, Bruno H. Stricker1,2*, Rikje Ruiter1# 1 Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands 2 The Health Care Inspectorate, The Hague, the Netherlands *Corresponding author: Bruno H. Stricker, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Netherlands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] #Submitting author: Rikje Ruiter, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Nether- lands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] Abstract Received date: July 09, 2016 Aim: Several studies in large databases suggest that in comparison to glucose-low- Accepted date: : September 05, 2016 ering sulfonylurea derivatives, metformin is associated with a reduced risk of cancer Publication date: September 12, 2016 in patients with diabetes. As many databases miss relevant confounder data, our objective was to investigate whether the determinants age, body mass index (BMI), alcohol consumption, and renal function were associated with dispensing of either Citation: Stricker, B.H., et al. The Dif- metformin or sulfonylurea derivatives as first drug therapy for type 2 diabetes mel- ferent Association between Metformin and litus while taking into account calendar time. Sulfonylurea Derivatives and the Risk of Methods: We identified 639 incident metformin users and 934 incident sulfonylurea Cancer May be Confounded by Body Mass derivatives users in the Rotterdam Study, a prospective population-based cohort Index.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Marked Improvement in Glycemic Control with Exenatide on Addition
    Journal of Diabetes Mellitus, 2018, 8, 152-159 http://www.scirp.org/journal/jdm ISSN Online: 2160-5858 ISSN Print: 2160-5831 Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience Salina Esmail1, Sonal Banzal2, Udaya M. Kabadi2,3* 1University of Iowa, Iowa City, IA, USA 2MGM College of Medicine, Indore, India 3Broadlawns Medical Center, Des Moines, IA, USA How to cite this paper: Esmail, S., Banzal, S. Abstract and Kabadi, U.M. (2018) Marked Improve- ment in Glycemic Control with Exenatide on Background: The major effect of Exenatide is attributed to lowering of Addition to Metformin, Sulfonylurea and post-prandial glycemia, whereas insulin glargine mainly improves fasting Insulin Glargine in Type 2 Diabetes Mellitus, glycemia [FPG]. Objective: Therefore, we assessed effect of Exenatide a Real World Experience. Journal of Diabetes Mellitus, 8, 152-159. administration at 6 months and for at 1 year on glycemic control, lipids, body https://doi.org/10.4236/jdm.2018.84015 weight [BW], daily insulin dose and hypoglycemic events. Methods: Records of 164 subjects, 126 men and 38 women administered Exenatide between Received: August 27, 2018 January 2011 and December 2013 are included in this report. Exenatide was Accepted: November 12, 2018 Published: November 15, 2018 initiated at 5 mcg subcutaneously twice daily [BID] in obese subjects, BMI > 30 kg/m2, with C-peptide > 1 ng/d, and HbA1c 7.5% - 9.5%, while receiving Copyright © 2018 by authors and daily metformin 2000 mg, Sulfonylurea Glimepiride 8 mg and insulin Glar- Scientific Research Publishing Inc.
    [Show full text]
  • Metformin Does Not Affect Cancer Risk: a Cohort Study in the U.K
    2522 Diabetes Care Volume 37, September 2014 Metformin Does Not Affect Cancer Konstantinos K. Tsilidis,1,2 Despoina Capothanassi,1 Naomi E. Allen,3 Risk: A Cohort Study in the U.K. Evangelos C. Rizos,4 David S. Lopez,5 Karin van Veldhoven,6–8 Clinical Practice Research Carlotta Sacerdote,7 Deborah Ashby,9 Paolo Vineis,6,7 Ioanna Tzoulaki,1,6 and Datalink Analyzed Like an John P.A. Ioannidis10 Intention-to-Treat Trial Diabetes Care 2014;37:2522–2532 | DOI: 10.2337/dc14-0584 OBJECTIVE Meta-analyses of epidemiologic studies have suggested that metformin may re- 1Department of Hygiene and Epidemiology, Uni- duce cancer incidence, but randomized controlled trials did not support this versity of Ioannina School of Medicine, Ioannina, hypothesis. Greece 2Cancer Epidemiology Unit, University of Oxford, EPIDEMIOLOGY/HEALTH SERVICES RESEARCH RESEARCH DESIGN AND METHODS Oxford, U.K. 3 A retrospective cohort study, Clinical Practice Research Datalink, was designed to Clinical Trial Service Unit, University of Oxford, Oxford, U.K. investigate the association between use of metformin compared with other anti- 4Lipid Disorders Clinic, Department of Internal diabetes medications and cancer risk by emulating an intention-to-treat analysis Medicine, University Hospital of Ioannina, Ioan- as in a trial. A total of 95,820 participants with type 2 diabetes who started taking nina, Greece 5 metformin and other oral antidiabetes medications within 12 months of their Division of Epidemiology, University of Texas School of Public Health, Houston, TX diagnosis (initiators) were followed up for first incident cancer diagnosis without 6Department of Epidemiology and Biostatistics, regard to any subsequent changes in pharmacotherapy.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Sulfonylurea Review
    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
    [Show full text]
  • Endocrinology, Diabetes and Metabolism Journal Research Open Volume 3 Issue 6
    Endocrinology, Diabetes and Metabolism Journal Research Open Volume 3 Issue 6 Review Article Sulfonylurea Use and Cardiovascular Safety Revisited Javier Morales Associate Clinical Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell University, New York *Corresponding author: Javier Morales, Associate Clinical Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell University, Vice President, Advanced Internal Medicine Group, East Hills, New York E-mail: [email protected] Received: October 23, 2019; Accepted: November 10, 2019; Published: November 15, 2019; Abstract Sulfonylurea use has been commonplace for the management of type 2 diabetes as an adjunct to metformin over the past decades. Their effectiveness has been repeatedly demonstrated in terms of glycemic control in the short-term however, long-term sustainable control remains in question. Over the years, FDA mandated cardiovascular safety trials have been completed involving most newer antidiabetic therapies to the market place however, the sulfonylurea class had not been studied until the recent head-to-head cardiovascular outcomes trial involving the comparison of linagliptin, an inhibitor of DPP-IV, with glimepiride in the CARMELINA study where non-inferiority was demonstrated in both treatment groups. While this finding seems to be reassuring, does it really confer safety of use of sulfonylurea drugs in the management of type 2 diabetes? Keywords: Sulfonylurea, DPP-IV inhibitor, diabetes, cardiovascular disease, major adverse cardiovascular event, type 2 diabetes, hypoglycemia, arrhythmia Guidelines on molecular formulation whereas glimepiride is noted to produce hypoglycemia in 2% to 4% patients compared to glyburide, noted to Since the evolution of the management of diabetes and produce hypoglycemia in 20-30% of patients with the reason being hyperglycemia, respected societies globally have been providing better preservation of prevention of insulin secretion and promotion guidance with respect to such management.
    [Show full text]